HYPOTHESIS | doi:10.20944/preprints202004.0151.v2
Online: 22 April 2020 (09:46:54 CEST)
Human respiratory beta coronavirus are emerging causes for Public Health Emergencies of International Concern (PHEIC). SARS-CoV2 is circulating worldwide since November 2019. We review here the cardiovascular morbidity and mortality in COVID-19, and data supporting the role for dysregulation of the RAS counterregulatory axis due to binding of SARS-CoV2 S protein to ACE2 receptor. Since this counterregulatory axis provides benefits not only on the cardiovascular front but also in acute lung injury, we speculate on potential use of ACE inhibitors and AT1R blockers in critically ill COVID-19 patients, and report current evidences.
CASE REPORT | doi:10.20944/preprints201801.0227.v1
Subject: Life Sciences, Other Keywords: Lactate dehydrogenase (LDH), Computed Tomography (CT), Glomerular filtration rate (GFR), C reactive protein (CRP), Angiotensin converting enzyme inhibitor (ACEI) Angiotensin receptor blocker (ARB), Kidney Urinary bladder ( KUB), Dimercapto Succinic Acid (DMSA)
Online: 24 January 2018 (11:41:15 CET)
Renal artery thrombosis is a sporadic serious clinical condition which potentially cause renal infarction. Diagnosis of renal infarction can be delayed or missed due to non specific clinical presentation and overlapping appearance of medical and surgical phenomena. Early diagnosis supported by biochemical and radiological findings while appropriate management potentially improve morbidity and mortality. Persistent abdominal or flank pain with raised LDH and proteinuria on background of thromboembolism risk factors supports the diagnosis. Despite the rarity of the disease rapid identification with prompt medical or endovascular intervention could prevent irreversible renal parenchymal damage.